EDAP TMS (FOCL) Proxy filing summary

Executive summary

• Annual General Meeting convened to present and approve 2025 statutory and consolidated financial statements.

• 2025 consolidated revenue was €62.4 million, with a consolidated net loss of €25.9 million under U.S. GAAP and IFRS.

• Significant product milestones included CE mark for Focal One Robotic HIFU in endometriosis and FDA 510(k) clearance for imaging improvements.

• €36 million credit facility secured from the European Investment Bank to support HIFU development and new clinical indications.

• Company to become a U.S. Domestic Filer effective January 1, 2026, aligning with SEC reporting requirements.

Voting matters and shareholder proposals

• Proposal to allocate 2025 net loss of €3,582,723 to retained earnings, increasing the debit balance.

• Renewal of co-statutory auditor AGILI3F’s term to be submitted for shareholder approval at the June 2026 AGM.

Board of directors and corporate governance

• Directors received €244,410 in compensation for 2025.

• Board strategy focuses on expanding HIFU business globally, especially in the U.S., and scaling back lithotripsy and distribution activities.